FDA grants Breakthrough Device designation to Natera multi-cancer blood test
Bitget2026/10/09 12:01Natera received FDA Breakthrough Device designation for its multi-cancer early detection blood test. The assay uses cell-free DNA to screen for multiple cancers, supporting an accelerated regulatory review pathway. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610090800BIZWIRE_USPR_____20261009_BW275528) on October 09, 2026, and is solely responsible for the information contained therein.
- Natera received FDA Breakthrough Device designation for its multi-cancer early detection blood test.
- The assay uses cell-free DNA to screen for multiple cancers, supporting an accelerated regulatory review pathway.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
United States Dollar Index remains subdued as lower oil prices ease inflation pressure
Silver Price Forecast: XAG/USD rises to near $53.00 as lower oil eases inflation pressure
Crypto prices
More
